Supplementary Material for: Adjunctive active vitamin D (AVD) decreases kidney function during treatment of secondary hyperparathyroidism (SHPT) with extended-release calcifediol (... by figshare admin karger (2628495)

Effects of TGF-β1 on the expression of fibrosis indicators in HBdSMCs and the effects of MEL on the expression of fibrosis indicators in HBdSMCs induced by TGF-β1. by Yang Zhang (30734)

VANGL2 recruits NLRP3 to OPTN for selective autophagic degradation. by Huaji Jiang (16907514)

OPG147 has no effect on TBK1 or IRF3-mediated ISRE activation and HT-DNA-induced signaling. by Xue-Mei Yi (18851202)

Mutagenesis of the CXCL10 binding site on <i>L</i>. <i>(L</i>.<i>) major</i> GP63 to <i>L</i>. <i>(V</i>.<i>) panamensis</i> residues reduces CXCL10 cleavage and T cell chemotaxis. by Alejandro L. Antonia (7147739)

“…Equal amounts of GP63 protein from each mutant were incubated with 50 mg/mL of azocasein for 24 hours. Cleaved azocasein was determined by measuring OD440 above background determined by a no transfection media control. …”

Minimum concentration of Amphotericin B in serum according to the formulation, dose, and daily or prolonged intermittent therapeutic regimen by Leticia Aparecida Schiave (8438409)

“…The geometric mean Cmin tended to decrease with a reduction in the dose and frequency of intermittent L-AmB infusions: 357 ng/mL (100 mg 4 to 5 times/week) > 263 ng/mL (50 mg 4 to 5 times/week) > 227 ng/mL (50 mg 1 to 3 times/week). …”

CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis by Yusuke Takahashi (19844)

Supplementary Material for: Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a... by figshare admin karger (2628495)

“…At randomization, iPTH had to be 300-<1,200 pg/mL, 25D <50 ng/mL, corrected serum calcium <9.8 mg/dL and phosphorus <6.5 mg/dL. …”

Additional file 2 of Single-cell profiling reveals periosteal signatures of impaired periosteal cells proliferation in a drill-hole model of type 2 diabetes by Xing Ji (3096735)

“…Osteoblasts were treated with vehicle or varying concentrations of FGL2 (50, 200 ng/mL) under normal (vehicle) and high glucose (4.5 mg/mL) conditions, and relative cell proliferation was assessed after 48 h to compare the effects under these different conditions. …”